281 related articles for article (PubMed ID: 18495955)
21. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
22. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
Setiady YY; Coccia JA; Park PU
Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
[TBL] [Abstract][Full Text] [Related]
23. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
[TBL] [Abstract][Full Text] [Related]
24. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
[TBL] [Abstract][Full Text] [Related]
25. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
26. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
Blood; 2009 Jun; 113(24):6161-71. PubMed ID: 19372261
[TBL] [Abstract][Full Text] [Related]
27. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
28. CD19: a promising B cell target for rheumatoid arthritis.
Tedder TF
Nat Rev Rheumatol; 2009 Oct; 5(10):572-7. PubMed ID: 19798033
[TBL] [Abstract][Full Text] [Related]
29. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
30. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
32. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging.
Montalvao F; Garcia Z; Celli S; Breart B; Deguine J; Van Rooijen N; Bousso P
J Clin Invest; 2013 Dec; 123(12):5098-103. PubMed ID: 24177426
[TBL] [Abstract][Full Text] [Related]
33. Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.
Ito D; Brewer S; Modiano JF; Beall MJ
Leuk Lymphoma; 2015 Jan; 56(1):219-25. PubMed ID: 24724777
[TBL] [Abstract][Full Text] [Related]
34. Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma.
Albanesi M; Mancardi DA; Macdonald LE; Iannascoli B; Zitvogel L; Murphy AJ; Daëron M; Leusen JH; Bruhns P
J Immunol; 2012 Dec; 189(12):5513-7. PubMed ID: 23150715
[TBL] [Abstract][Full Text] [Related]
35. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice.
Kolomansky A; Kaye I; Ben-Califa N; Gorodov A; Awida Z; Sadovnic O; Ibrahim M; Liron T; Hiram-Bab S; Oster HS; Sarid N; Perry C; Gabet Y; Mittelman M; Neumann D
Front Immunol; 2020; 11():561294. PubMed ID: 33193330
[TBL] [Abstract][Full Text] [Related]
38. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
39. Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms.
Lykken JM; Horikawa M; Minard-Colin V; Kamata M; Miyagaki T; Poe JC; Tedder TF
Blood; 2016 Apr; 127(15):1886-95. PubMed ID: 26888257
[TBL] [Abstract][Full Text] [Related]
40. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]